title: Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
abstract: We have demonstrated that polyvalent antiimmunoglobulin antibodies directed at appropriate cell surface light (L) or heavy (H) immunoglobulin (Ig) chains will inhibit proliferation and the expression of c-myc and mu-Ig chain mRNA in Burkitt's lymphoma (BL) cell lines bearing 8;14 chromosomal translocations. This effect was not observed in BL cell lines bearing 8;22 translocations or in BL cell lines which did not express surface Ig or in karyotypically normal Epstein-Barr virus-transformed lymphoblastoid cell lines. The antiproliferative effect was reproducible and resulted in cell death in the most sensitive cell lines. The decrease in gene expression preceded the antiproliferative effect. The effect of anti-Ig on gene expression was relatively specific since the level of total (shown by Northern blots) and cytoplasmic (dot blots) mRNA of several other genes (beta-actin, G6PD, kappa-L chain) and the first exon of c-myc (in cell lines in which this exon is expressed separately from the second and third exons) was not changed in these same BL cell lines. Expression of both c-myc and mu was maximally inhibited between 3 and 6 h after the addition of anti-Ig. In the most sensitive BL cell line, concurrent reduction in c-myc and mu mRNA was noted as early as 1 h after anti-Ig and the nadir of expression of these genes occurred at 3 h. These results indicate that the deregulated high constitutive expression of c-myc in some BLs can be down-regulated by anti-Ig resulting in inhibition of proliferation and cell death. In addition these data are consistent with the possibility that in at least some 8;14 bearing BLs the malignant transformation occurs in an immature B-cell undergoing antigen-independent differentiation.
authors.affiliation: Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892.
authors.forename: V E
authors.initials: VE
authors.lastname: Arasi
authors.forename: R
authors.initials: R
authors.lastname: Lieberman
authors.forename: J
authors.initials: J
authors.lastname: Sandlund
authors.forename: J
authors.initials: J
authors.lastname: Kiwanuka
authors.forename: L
authors.initials: L
authors.lastname: Novikovs
authors.forename: I
authors.initials: I
authors.lastname: Kirsch
authors.forename: G
authors.initials: G
authors.lastname: Hollis
authors.forename: I T
authors.initials: IT
authors.lastname: Magrath
mesh_terms: D000906:Antibodies / Q000276:immunology*; D015152:Blotting, Northern; D002051:Burkitt Lymphoma / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D002455:Cell Division; D002460:Cell Line; D005803:Genes, Immunoglobulin; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics / Q000276:immunology*; D007147:Immunoglobulin Light Chains / Q000276:immunology*; D007700:Kinetics; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016271:Proto-Oncogene Proteins c-myc; D011519:Proto-Oncogenes; D012333:RNA, Messenger; D011947:Receptors, Antigen, B-Cell / Q000276:immunology*; D014158:Transcription, Genetic
chemical_list: D000906:Antibodies; D007143:Immunoglobulin Heavy Chains; D007147:Immunoglobulin Light Chains; D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D011947:Receptors, Antigen, B-Cell